Therapeutic validation of an orphan G protein-coupled receptor: the case of GPR84 by Marsango, Sara et al.
R E V I EW AR T I C L E T H EM ED I S S U E
Therapeutic validation of an orphan G protein‐coupled
receptor: The case of GPR84
Sara Marsango | Natasja Barki | Laura Jenkins | Andrew B. Tobin |
Graeme Milligan
Centre for Translational Pharmacology,
Institute of Molecular, Cell and Systems
Biology, College of Medical, Veterinary and
Life Sciences, University of Glasgow,
Glasgow, UK
Correspondence
Graeme Milligan, Centre for Translational
Pharmacology, Institute of Molecular, Cell and
Systems Biology, College of Medical,
Veterinary and Life Sciences, University of
Glasgow, Glasgow G12 8QQ, UK.
Email: graeme.milligan@glasgow.ac.uk
Funding information
Sosei Heptares; Biotechnology and Biological
Sciences Research Council, Grant/Award
Number: BB/T000562/1
Despite the importance of members of the GPCR superfamily as targets of a
broad range of effective medicines many GPCRs remain poorly characterised.
GPR84 is an example. Expression of GPR84 is strongly up regulated in immune
cells in a range of pro‐inflammatory settings and clinical trials to treat idiopathic
pulmonary fibrosis are currently ongoing using ligands with differing levels of
selectivity and affinity as GPR84 antagonists. Although blockade of GPR84 may
potentially prove effective also in diseases associated with inflammation of the
lower gut there is emerging interest in defining if agonists of GPR84 might find
utility in conditions in which regulation of metabolism or energy sensing is
compromised. Here, we consider the physiological and pathological expression
profile of GPR84 and, in the absence of direct structural information, recent
developments and use of GPR84 pharmacological tool compounds to study its
broader role and biology.
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1 | INTRODUCTION
GPR84 is a poorly characterised Gi‐coupled, class A GPCR mainly
expressed by immune cells, including monocytes, macrophages
and neutrophils in the periphery, and microglia in the brain
(Wojciechowicz & Ma'ayan, 2020). Because GPR84 transcript is up‐
regulated in many pro‐inflammatory conditions, potential therapeutic
opportunity in targeting this receptor in inflammatory conditions,
including ulcerative colitis and fibrotic diseases, has been suggested
(Gagnon et al., 2018; Suzuki et al., 2013; Vermeire et al., 2017;
Wojciechowicz & Ma'ayan, 2020). Identified almost two decades
ago (Wittenberger, Schaller, & Hellebrand, 2001; Yousefi, Cooper,
Potter, Mueck, & Jarai, 2001), human GPR84 encodes a protein of
396 amino acids that shares 85% identity with the protein encoded
by murine Gpr84. The extensive intracellular loop 3 (ICL3) provides
most of the differences between these orthologues, while the
predicted transmembrane domains have only 14 amino acid
differences. Although it is widely accepted that medium‐chain fatty
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acids (MCFAs), particularly those with 10–12 carbon acids (decanoic
acid [C10], undecanoic acid [C11], and lauric acid [C12]), can bind
to and activate GPR84 (Nikaido, Koyama, Yoshikawa, Furuya, &
Takeda, 2015; Southern et al., 2013; Suzuki et al., 2013; Wang, Wu,
Simonavicius, Tian, & Ling, 2006), officially, GPR84 remains an
orphan receptor (Sharman et al., 2011). This reflects that MCFAs
display only modest potency in activating GPR84. In recombinant
expression systems, the reported potency of MCFAs to either
inhibit forskolin‐stimulated cAMP production or to stimulate [35S]
guanosine 5‐O‐(3‐thiotriphosphate) ([35S]GTPγS) binding via GPR84
is in the low micromolar range. However, millimolar concentrations
of C10–C12 fatty acids are required to induce secretion of the pro‐
inflammatory cytokine IL‐12 p40, by LPS (which acts to up‐regulate
levels of both mRNA and GPR84 protein; Mancini et al., 2019) in
RAW264.7 cells. This suggests, as is often the case with various
agonist studies, that estimates of agonist potency in transfected cell
systems (Table 1) incorporate various levels of receptor reserve and
often markedly overestimate ligand binding affinity at the receptor
(Bolognini et al., 2019; Bradley et al., 2018). Because of this, we will
avoid ascribing absolute agonist affinity values unless these have
been generated by a reliable method, such as mathematical analysis
of operational models (Ehlert, 2005) of the extent of allosteric mod-
ulation between ligands (Al Mahmud et al., 2017) that bind to
distinct sites of GPR84 (Table 1) and limit comments to relative
potency of compounds where these have been assessed in parallel
using the same experimental system, for example, direct measures
of EC50 employing functional assays of second messenger regulation
or G‐protein activation in cell lines transfected to express an
orthologue of GPR84. As such, levels of MCFAs circulating in the
plasma (approx. 0.5 mM) might be too low to substantially activate
GPR84 in vivo (Al Mahmud et al., 2017; Mancini et al., 2019).
Here, as well as discussing the expression profile of GPR84 in
physiological and pathophysiological conditions, we will consider the
portfolio of available ligands that can be used as tool compounds to
study the function and biology of GPR84 and how limitations of
these are currently restricting a full understanding of the therapeutic
potential of this receptor. As noted above, although MCFAs
certainly can activate GPR84, the modest potency of these in native
systems has promoted efforts to identify and characterise other,
more potent agonists. Moreover, as GPR84 is linked to various
inflammatory diseases, efforts have also been made to identify
antagonists to assess if these might have therapeutic utility in such
settings.
It is assumed here that MCFAs act as orthosteric agonists,
although while GPR84 remains classified as an orphan GPCR, this
must remain a presumptive definition (Figure 1 and Table 1). Of
key importance is that, although MCFAs do activate GPR84,
equivalent fatty acid amides do not (Nikaido et al., 2015), and the
requirement for the acid function was also observed when
decanoic acid (C10) was replaced with its ester, methyl decanoate
(Al Mahmud et al., 2017). Although this defines the importance of
the acid function for binding and/or activation, in the absence of
suitable atomic‐level structures, the potential orientation of the
MCFA in the binding site remains a matter of conjecture. In class
A GPCRs, the orthosteric binding site is typically a deep pocket
leading from the extracellular side of the receptor with which
endogenously produced ligands interact (Congreve, de Graaf,
Swain, & Tate, 2020). By contrast, binding sites that are
topographically distinct from the orthosteric site are generically
described as allosteric (Congreve et al., 2020). Given that other
class A GPCRs that respond to either short‐chain (free fatty
acid receptors 2 and 3) or long‐chain (free fatty acid receptors 1
and 4) fatty acids have specific arginine residues as part of the
orthosteric binding pocket that act to co‐ordinate the carboxylate
of the appropriate fatty acid (Milligan, Shimpukade, Ulven, &
Hudson, 2017), Al Mahmud et al. (2017) assessed whether this
might also be true for GPR84, even though this receptor is not
closely related to any of the currently IUPHAR‐accepted free fatty
acid receptors (Alexander, Christopoulos et al., 2019). A chimeric
homology model that noted and took into account the high similar-
ity of the second extracellular loop of GPR84 with that of rhodop-
sin, for which atomic‐level structures were known, suggested that
Arg172 from this region would potentially face into the binding
pocket and anchor the fatty acid carboxylate (Tikhonova, 2017).
Mutation of this residue to alanine, and indeed even to lysine,
abolished function of MCFAs. By contrast, the potency of a known
allosteric agonist (see later) of GPR84, 3,3′‐diindolylmethane (DIM),
was unaffected by these mutations (Al Mahmud et al., 2017).
Co‐ordination of the fatty acid carboxylate by this arginine implied
that the alkyl chain of the fatty acid would penetrate down into
the orthosteric cavity of the receptor with the carboxylate at the
extracellular interface. In contrast, earlier mutagenesis and
homology modelling studies by Nikaido et al. (2015) concluded that
the opposite orientation of the fatty acid was more likely, with the
carboxylate reaching downwards into the receptor. Mutagenesis
and homology modelling studies by Köse et al. (2020) have
supported this orientation, showing the fatty acid carboxylate in
the binding cleft and forming hydrogen‐bond interactions with
Tyr69, Asn104, and Asn357. In this model, Arg172 contributes
indirectly to agonist–receptor interaction, possibly by playing a role
in initial ligand recognition (Köse et al., 2020). It also appears that
MCFAs with a hydroxyl group at the 2‐ or 3‐position can activate
GPR84 more potently than non‐hydroxylated MCFAs (Suzuki
et al., 2013). Hydroxylation at other positions on the fatty acid
alkyl chain is also consistent with activation of the receptor
(Kaspersen, Jenkins, Dunlop, Milligan, & Ulven, 2017).
2 | ORTHOSTERIC AGONISTS
2.1 | Embelin (2,5‐dihydroxy‐3‐undecyl‐
1,4‐benzoquinone)
Embelin (2,5‐dihydroxy‐3‐undecyl‐1,4‐benzoquinone) is a natural
product derived from the plant Embelia ribes, used in traditional
Chinese medicine for treatment of diverse conditions, such as
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gastrointestinal and inflammatory diseases (Gaidarov et al., 2018). It
was first described in the patent literature as a potent and efficacious
GPR84 agonist using inhibition of cAMP assays (Hakak et al., 2007).
Although appreciated for a period of time to have such activity by
those working in the field, it was a number of years before this was
confirmed in the peer‐reviewed literature (Al Mahmud et al., 2017;
Southern et al., 2013; Wei et al., 2017). Embelin consists of a polar
dihydroxybenzoquinone head group and an 11‐carbon alkyl chain tail
(Figure 1). Truncation of the alkyl chain length to 7 or 8 carbons










with DIM towards Gi‐mediated
adenylyl cyclase inhibition over
arrestin recruitmente
Zhang et al., 2016
Al Mahmud et al., 2017
Pillaiyar et al., 2017
Mancini et al., 2019
Note: Note comments in the text about reported potency values and potential issues of receptor reserve.
aPotency values were generated using [35S]GTPγS assay.
bPotency values were generated using cAMP assay.
cPotency values were generated using β‐arrestin recruitment assay.
dKöse et al. (2020).
ePillaiyar et al. (2017) and Mancini et al. (2019).
F IGURE 1 Chemical structures of low
MW GPR84 ligands. The chemical
structure of some widely used ligands
with actions at GPR84 is shown. The
alphabetical labelling system (A–O) is used
to define which ligands were employed in
studies highlighted in Figure 2 and
Tables 1 and 2
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derivatives containing very short (C3) or very long (C15) alkyl chains
(Gaidarov et al., 2018). Embelin has a range of biological activities
including inhibition of the X‐linked inhibitor of apoptosis protein and
activation of caspase 9, as well as antioxidant properties (Nikolovska‐
Coleska et al., 2004). Even at other GPCRs, embelin has been noted
to have as potent actions, as at GPR84, but rather as a blocker; for
example, at the chemokine receptor CXCR2 (Ki = 93 nM) and the
adenosine A3 receptor (Ki = 1.4 μM). However, at least at these
receptors, the C7 derivative reportedly lacks activity (Gaidarov
et al., 2018). As such, embelin and derivatives have been used to
characterise roles of GPR84 in a variety of settings (Table 1) (Al
Mahmud et al., 2017; Gaidarov et al., 2018; Wei et al., 2017).
2.2 | 6‐OAU (6‐(octylamino) pyrimidine‐2,4(1H,3H)‐
dione)
6‐OAU (6‐(octylamino) pyrimidine‐2,4(1H,3H)‐dione) is a further
example of a GPR84 agonist characterised by a polar head group and
alkyl tail (Figure 1 and Table 1) (Recio et al., 2018; Suzuki et al., 2013;
Wei et al., 2017). 6‐OAU is able to induce chemotaxis of human poly-
morphonuclear leukocytes (PMNs) and macrophages and to promote
production of the pro‐inflammatory cytokine IL‐8 from PMNs, and
TNF‐α, IL‐6, IL‐12B, as well as the chemokines CCL2, CCL5 and
CXCL1 from bone marrow‐derived macrophages previously treated
with LPS (Recio et al., 2018; Suzuki et al., 2013). These were clearly
GPR84‐mediated inflammatory responses as they were absent in cells
isolated from homozygous GPR84 knockout mice and when such
macrophages were treated with a selective GPR84 antagonist (see
later) (Recio et al., 2018). In such LPS‐stimulated bone marrow‐derived
macrophages, treatment with 6‐OAU enhanced phosphorylation of
PKB (Akt) and the ERK1/2 and promoted p65 nuclear translocation
(Recio et al., 2018). A series of analogues of 6‐OAU have also been
generated by modifying the uracil head to incorporate alternative
groups (Pillaiyar et al., 2018). Among 66 reported new derivatives in
this study, a few have been considered in detail, based on improved
potency, selectivity and metabolic stability. 6‐Hexylamino‐2,4(1H,3H)‐
pyrimidinedione (PSB‐1584) (Figure 1) is reportedly some 100 times
more potent than 6‐OAU in activating GPR84 (Pillaiyar et al., 2018).
Homology modelling and docking studies have attempted to provide
insights into the structural basis for the higher potency of uracil deriv-
atives, particularly when compared with embelin and decanoic acid
(Köse et al., 2020). These studies predicted a stronger interaction of
uracil derivatives with residues Asn357 and Asn104, which may form
part of the binding pocket of GPR84, as suggested initially by Köse
et al. (2020) and Nikaido et al. (2015). However, while of interest, the
dopamine D3 receptor bound by the antagonist eticlopride, which
was used to develop the GPR84 homology model, is far removed from
GPR84 in terms of overall sequence similarity, and thus, these predic-
tions must be viewed as tentative. A tritium‐labelled form of PSB‐
1584 ([3H]PSB‐1584) shows high affinity for GPR84 (KD approx.
2 nM) (Table 1) (Köse et al., 2020), and [3H]PSB‐1584 has been used
to quantify GPR84 in membrane preparations from cells and from
human, rodent and bovine tissues (Köse et al., 2020). However, it may
also bind to non‐GPR84 targets. Non‐transfected HEK293 cells do
not express functional GPR84, but substantial levels of specific bind-
ing of [3H]PSB‐1584 were reported by Köse et al. (2020). Whilst it is
well established that activation of GPR84 results in selective activa-
tion of Pertussis toxin‐sensitive, Gi‐family G proteins, agonist‐occupied
GPR84 can also interact with arrestins (Lucy et al., 2019; Pillaiyar
et al., 2018; Southern et al., 2013; Zhang et al., 2016). Compounds
that display different potency profiles at distinct endpoints (e.g.,
G‐protein activation and interaction with an arrestin) are described as
displaying “bias” in relation to each other. Although this is normally
compared with the action of the endogenous agonist(s), the fact that
MCFAs are not fully accepted as the natural activators of GPR84
makes the selection of the appropriate reference agonist more
complex in this case. However, the ligands 6‐((p‐chloro‐phenylethyl)
amino)‐2,4(1H,3H)‐pyrimidinedione and 6‐((p‐bromo‐phenylethyl)
amino)‐2,4(1H,3H)‐pyrimidinedione (PSB‐16434 and PSB‐17365,
respectively; Figure 1) show a marked preference for activating G
protein over interacting with arrestin (when compared with embelin)
(Pillaiyar et al., 2018).
2.3 | Alkylpyrimidine‐4,6‐diol derivatives
Based on a high‐throughput screening hit, a series of alkylpyrimidine‐
4,6‐diol derivatives were identified as novel and potent GPR84 ago-
nists (Liu et al., 2016; Zhang et al., 2016). These include 2‐(hexylthio)
pyrimidine‐4,6‐diol (also referred to as ZQ‐16, Sundqvist et al., 2018;
Zhang et al., 2016; 2‐HTP, Mancini et al., 2019; or compound 1, Al
Mahmud et al., 2017; Liu et al., 2016) and 6‐nonylpyridine‐2,4‐diol,
potentially the most potent agonist of GPR84 reported to date
(Figure 1 and Table 1) (Liu et al., 2016; Zhang et al., 2016).
2.4 | DL‐175 (3‐(2‐((4‐chloronaphthalen‐1‐yl)oxy)
ethyl)pyridine 1‐oxide)
DL‐175 (3‐(2‐((4‐chloronaphthalen‐1‐yl)oxy)ethyl)pyridine 1‐oxide)
was identified using a virtual screen based on comparisons with
6‐OAU (Figure 1). This would suggest it also should be an orthosteric
agonist (Lucy et al., 2019). Using a recombinant cell system, DL‐175
showed comparable potency and efficacy to 6‐OAU in inhibiting
cAMP accumulation; however, it was ineffective in an arrestin recruit-
ment assay, indicating a marked bias for G‐protein signalling (Table 1)
(Lucy et al., 2019). Interestingly, although not inducing signals in mac-
rophages derived from GPR84 knockout mice (Lucy et al., 2019),
DL‐175 generated a distinct signalling profile from 6‐OAU in both
primary murine bone marrow‐derived macrophages and phorbol
myristate acetate (PMA)‐differentiated human U937 macrophage‐like
cells (Lucy et al., 2019). This may reflect the distinct bias of DL‐175
away from arrestin interactions as this would be anticipated to limit
potential desensitisation. Interestingly, when cells were pretreated
with CMPD101, a combined GPCR kinase GRK2 and GRK3 inhibitor
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(Ikeda, Kaneko, & Fujiwara, 2007), the response to 6‐OAU now
resembled that of DL‐175 (Lucy et al., 2019). Finally, in contrast with
6‐OAU, DL‐175 failed to promote chemotaxis of M1‐polarised U937
macrophages (Lucy et al., 2019). Despite these interesting
characteristics, DL‐175 is rapidly metabolised when exposed to
mouse hepatocytes, suggesting that it will be of limited use for in vivo
studies (Lucy et al., 2019).
3 | ALLOSTERIC AGONISTS
3.1 | DIM (3,3′‐methylenebis‐1H‐indole)
DIM (3,3′‐methylenebis‐1H‐indole) (Figure 1 and Table 1) is a metabo-
lite produced in vivo from indole‐3‐carbinol, which is present at high
levels in some vegetables including broccoli and kale (Wang, Schoene,
Milner, & Kim, 2012). As with some of the orthosteric agonists
described above, DIM can activate several targets including the aryl
hydrocarbon (Yin, Chen, Mao, Wang, & Chen, 2012) and oestrogen
(Marques et al., 2014) receptors. Although the mechanistic basis
remains unclear, it also generates anti‐obesity effects in mice (Seo
et al., 2011) and has anticancer activity both in vitro and in vivo
(Fares, 2014; Firestone & Bjeldanes, 2003; Kiselev et al., 2014). It is
unlikely to mediate these effects via activation of GPR84. Initially,
DIM was described as a non‐lipid‐like GPR84 agonist by Takeda
et al. (2003). However, the lack of structural relatedness to MCFAs
and that it acts to enhance the actions of C10 as well as other
orthosteric agonists at GPR84, defined DIM as behaving as a positive
allosteric modulator (PAM) as well as a direct agonist (ago‐PAM) at
GPR84 (Al Mahmud et al., 2017; Nikaido et al., 2015). As DIM is pro-
duced in vivo it has been suggested that it might enhance the potency
of MCFAs sufficiently to allow circulating and local concentrations of
MCFAs to activate GPR84 effectively. As noted earlier, the direct
agonist effects of DIM are unaffected by mutagenesis of Arg172,
hence confirming the binding site, or the route of entry to this binding
site, to be distinct from the MCFAs and other orthosteric agonists
(Al Mahmud et al., 2017). Although analysis of the positive allosteric
interactions between DIM and MCFAs at GPR84 has allowed
calculation that DIM binds (KA range 5.6–6.9 μM) with some 200‐fold
higher affinity than MCFAs (KA range 0.17–0.53 mM) (Al Mahmud
et al., 2017), it is still only a moderately potent activator. A more
recent study confirmed DIM (and its derivatives) to be a positive
allosteric modulator of GPR84 based on its ability to increase binding
of [3H]PSB‐1584 (Köse et al., 2020). As expected from the concept of
“probe dependence” of allosteric effects (Bartuzi, Kaczor, &
Matosiuk, 2018), DIM displays different levels of co‐operativity with
different orthosteric agonists of GPR84 (Al Mahmud et al., 2017)
consistent with these binding and promoting receptor activation in
somewhat different ways. As with 6‐OAU, Pillaiyar et al. (2017) and
Pillaiyar et al. (2018) have performed extensive structure–activity
studies designed to identify analogues with improved potency. This
has been moderately successful. Both di(5‐fluoro‐1H‐indole‐3‐yl)
methane (PSB‐15160) and di(5,7‐difluoro‐1H‐indole‐3‐yl)methane
(PSB‐16671) (Figure 1) are somewhat more potent than DIM but dis-
play bias, compared with DIM, towards Gi‐mediated AC inhibition
over arrestin recruitment (Pillaiyar et al., 2017). While both PSB‐
15160 and PSB‐16671 are markedly selective for GPR84, compared
with the long‐chain free fatty acid receptors FFA1 and FFA4 (Pillaiyar
et al., 2017), at least PSB‐16671 possesses currently undefined
off‐target liabilities. For example, PSB‐16671 was equally effective in
activating G proteins in mouse bone marrow‐derived neutrophils
isolated from both wild‐type and GPR84 knockout mice (Mancini
et al., 2019). As the parental ligand DIM did not display this character-
istic, then the markedly greater efficacy of PSB‐16671 in membranes
from a mouse GPR84‐expressing HEK293‐derived cell line when mea-
suring binding of [35S]GTPγS is most likely a reflection of this
off‐target effect rather than substantially higher efficacy of PSB‐
16671 over DIM at GPR84 (although a somewhat higher level of
efficacy of PSB‐16671, compared with DIM, was observed in a
recombinant cell system [Flp‐In T‐REx‐293 cells] expressing human
GPR84; Mancini et al., 2019). This conclusion is supported by the
observation that a GPR84 antagonist (see later) only partly blocked
the effect of PSB‐16671 in such membranes, whereas the stimulation
produced by DIM was fully attenuated by the same antagonist
(Mancini et al., 2019). Moreover, the same GPR84 antagonist fully
blocked [35S]GTPγS binding in membranes prepared from human neu-
trophils indicating on‐target effects (Mancini et al., 2019). An obvious
feature across the range of GPR84 agonists, whether potentially
orthosteric or allosteric, is that when effects specifically reflecting
activation of GPR84 are compared, the potencies of compounds at
human and mouse receptors are very close. This may not be consid-
ered particularly surprising given the noted high sequence similarity in
the transmembrane and extracellular regions of these orthologues,
but interestingly, this is not true for the best characterised class of
currently described GPR84 antagonists (Mancini et al., 2019).
4 | ANTAGONISTS
The best characterised GPR84 antagonists are from a series of
dihydropyrimidinoisoquinolinones described initially by Labéguère,
Alvey, Newsome, Saniere, and Fletcher (2014) (Table 2). A member of
this series, 9‐cyclopropylethynyl‐2‐((S)‐1‐[1,4]dioxan‐2‐ylmethoxy)‐
6,7‐dihydropyrimido[6,1‐a]isoquinolin‐4‐one (GLPG1205) (Figure 1
and Table 2), progressed into first‐in‐human clinical trials for the
potential treatment of ulcerative colitis but failed to achieve defined
levels of efficacy despite reducing disease activity and neutrophil
infiltration in a mouse model of chronic inflammatory bowel disease
(IBD), induced by dextran sodium sulphate (Labéguère et al., 2020).
These ligands have the characteristics of non‐competitive antagonists
of GPR84 (as least as defined by the nature of their blockade of the
action of “orthosteric” agonists as defined above) (Al Mahmud
et al., 2017; Labéguère et al., 2020) and also act as non‐competitive
blockers of the effects of the group of allosteric agonists represented
by DIM (Al Mahmud et al., 2017). In addition to a number of
compounds from this series that have been shown to block effects of
6 MARSANGO ET AL.
GPR84 agonists in a variety of settings (Table 2) (Al Mahmud
et al., 2017; Mancini et al., 2019; Sundqvist et al., 2018), [3H]G9543
(a tritiated version of “compound 38” described in Labéguère
et al., 2020) has been instrumental in demonstrating that
pro‐inflammatory signals such as exposure to LPS act to up‐regulate
levels of the receptor at protein as well as mRNA level (Mancini
et al., 2019). In agreement with the characterisation of these
dihydropyrimidinoisoquinolinones as non‐competitive antagonists,
although different compounds from the same series are able to fully
displace the specific binding of [3H]G9543 from GPR84, neither
orthosteric nor allosteric agonists can do so (Al Mahmud et al., 2017;
Labéguère et al., 2020). Unlike the agonists, this class of antagonist
shows somewhat lower (between 20‐fold and 70‐fold in various set-
tings and reports) affinity at mouse GPR84, compared with the human
orthologue (Labéguère et al., 2020; Mancini et al., 2019). In practice,
this has meant that [3H]G9543 is not useful for quantification of
levels of expression of GPR84 in mouse tissues or mouse‐derived cell
lines. The basis for this difference remains undefined but once again,
as with the orientation of MCFAs, is likely be to fully understood only
when appropriate atomic‐level structures become available. Currently,
the only described compound with GPR84 antagonist activity that is
likely to act in an orthosteric fashion is PBI‐4050 (2‐(3‐pentylphenyl)
acetic acid) (Parker et al., 2017) (Figure 1 and Table 2) as this is a fatty
acid derivative. Although it is able to block GPR84, its affinity at the
receptor is very modest, and hence, formal proof of a competitive
orthosteric mode of action is difficult to achieve. Moreover, although
PBI‐4050 is currently the subject of a variety of clinical trials (see
Khalil et al., 2019), it clearly has actions at receptors other than
GPR84. Indeed, Gagnon et al. (2018) noted its ability to agonise the
long‐chain fatty acid receptor FFA1, and our own studies have noted
effects also at the short‐chain fatty acid receptor FFA2.
5 | EXPRESSION PROFILE OF GPR84
Transcriptome studies have revealed that GPR84 is expressed primar-
ily in a subset of peripheral immune cells (Figure 2). Following initial
identification on peripheral blood leukocytes (Yousefi et al., 2001),
subsequent studies confirmed high expression of GPR84 mRNA in
both human and mouse neutrophils and macrophages (Bouchard,
Page, Bedard, Tremblay, & Vallieres, 2007; Lattin et al., 2008;
Sundqvist et al., 2018; Suzuki et al., 2013; Wang et al., 2006). Rela-
tively lower levels of GPR84 mRNA transcript have been reported in
other immune cells, including dendritic cells, T cells, and B cells
TABLE 2 Antagonist ligands with affinity at GPR84
Compound
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aPotency values were generated using [35S]GTPγS assay.
bPotency values were generated using BRET activation biosensor assay.
cAl Mahmud et al. (2017), Mancini et al. (2019), and Labéguère et al. (2020).
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(Suzuki et al., 2013; Wang et al., 2006), and in microglial cells in the
CNS (Gautier et al., 2012; Hickman et al., 2013; Recio et al., 2018).
Although limited, expression has been detected outside the immune
system. For example, some studies have found GPR84 mRNA in
adipocytes, epithelial cells, fibroblast, and podocytes (Abdel‐Aziz
et al., 2016; Gagnon et al., 2018; Nagasaki et al., 2012). Receptor
expression in many of these tissues could possibly be due to immune
cells resident in these tissues, but this has yet not been confirmed.
6 | GPR84 UP-REGULATION IS
ASSOCIATED WITH PRO-INFLAMMATORY
CONDITIONS
Up‐regulation of GPR84 in immune cells at both mRNA and protein
levels has been reported in response to inflammatory conditions and
stimuli. Recent examples of such observations include that treatment
of human and mouse macrophages and the human monocytic cell line
F IGURE 2 GPR84 modulation in inflammatory conditions. Upper panel: Activation of GPR84 by orthosteric and allosteric ligands generates
pro‐inflammatory responses in different cell types. Lower panel: GPR84 inhibition reduces responses associated with inflammation, fibrosis, and
metabolic diseases in multiple cell types and tissues (letters indicate use of ligands illustrated in Figure 1)
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THP‐1 with the TLR4 activator LPS caused up‐regulation of GPR84
expression (Mancini et al., 2019; Recio et al., 2018). Similar outcomes
are obtained in vivo, where up‐regulation of GPR84 mRNA expression
was observed during acute inflammation in a mouse model of
endotoxemia. Additionally, up‐regulation was also observed in models
of chronic inflammation, including diabetes and atherosclerosis
(Recio et al., 2018). Consistent with the notion that GPR84 is a
pro‐inflammatory receptor, increase in GPR84 expression has also
been reported in colonic tissues and blood samples of patients with
IBD (Arijs et al., 2011; Planell et al., 2017). As previously noted, it
remains unclear to what extent GPR84 up‐regulation in these tissues
can be attributed to immune cell infiltration. However, the studies of
Arijs et al. (2011) have been quoted as a driver leading to the
assessment of whether blockade of GPR84 with the antagonist
GLPG1205 might improve clinical observations in patients with
ulcerative colitis (Labéguère et al., 2020).
Although up‐regulation of GPR84 has been primarily studied in
immune cells, a limited number of studies have also observed
up‐regulation in fat cells (Figure 2). GPR84 expression in human
adipocytes is significantly up‐regulated following acute exposure to
IL‐33, TNF‐α, or IL‐1β. This increase, however, was reported to be
transitory, since the increase in receptor mRNA expression was not
present following 24 h of exposure (Muredda, Kepczynska, Zaibi,
Alomar, & Trayhurn, 2018; Zaibi, Kepczynska, Harikumar, Alomar, &
Trayhurn, 2018). Similar observations have been made with treatment
of mouse 3T3‐L1 adipocytes with TNF‐α and LPS and in human
adipose‐derived stem cells (Nagasaki et al., 2012). Up‐regulation of
GPR84 mRNA was also observed in vivo, specifically in fat pads of
mice fed with a high‐fat diet. Interestingly, a correlation was reported
between receptor mRNA up‐regulation and increase in specific
staining for macrophages, suggesting infiltration of immune cells as
the likely cause of receptor up‐regulation (Nagasaki et al., 2012). An
increase in GPR84 mRNA transcripts has also been reported in liver
biopsies of patients with non‐alcoholic fatty liver disease (NAFLD).
This increase, however, is associated with inflammation rather than
fat accumulation in the liver (Puengel et al., 2020). In line with other
reports, higher levels of GPR84 mRNA have been observed in
fibroblasts, podocytes, proximal tubule epithelial cells, and
macrophages under fibrotic conditions (Gagnon et al., 2018; Grouix
et al., 2018; Li et al., 2018). Interestingly, this up‐regulation is also
accompanied by up‐regulation of various pro‐fibrotic and inflamma-
tory biomarkers, and treatment with PBI‐4050 significantly reduced
the expression of these markers (Gagnon et al., 2018; Grouix
et al., 2018; Li et al., 2018). Such observations underpin the clinical
trials of both PBI‐4050 (Khalil et al., 2019) and more recently
GLPG1205 (Labéguère et al., 2020) in idiopathic pulmonary fibrosis.
Unsurprisingly, promising initial results have promoted ideas that
blockade of GPR84 might be of more general use in a wider range of
fibrotic conditions (Nguyen et al., 2020; Wojciechowicz &
Ma'ayan, 2020). The exact mechanism responsible for disease‐induced
GPR84 up‐regulation in many in vivo studies remains to be identified.
Nevertheless, these studies further highlight the potential role of the
receptor in disease conditions primarily associated with inflammation.
Furthermore, observations of GPR84 up‐regulation are not limited to
peripheral diseases but have also been demonstrated in neuro-
inflammatory conditions in the CNS. Although low‐level expression of
GPR84 was reported in the brain of healthy adult mice in early studies
(Bouchard et al., 2007), inflammatory stimuli induce significant up‐
regulation in CNS microglia, for example, in a model of endotoxic
shock (Audoy‐Remus et al., 2015). TNF‐α and IL‐1 have been
suggested to play a key role in GPR84 up‐regulation, as mice lacking
these molecules show reduced expression of GPR84 in the cerebral
cortex (Bouchard et al., 2007). Higher levels of receptor mRNA
expression are also reported in other animal disease models affecting
the CNS, these include experimental autoimmune encephalomyelitis,
a model of multiple sclerosis (Bouchard et al., 2007), cuprizone‐induced
demyelination and axotomy (Bedard, Tremblay, Chernomoretz, &
Vallieres, 2007), and in a murine model of Alzheimer's disease
(APP‐PS1) (Audoy‐Remus et al., 2015). Many of these reports now are
now ready to be followed up, with the availability of a substantially
wider range of pharmacological tools, than at the time of the original
observations.
Not surprisingly, given the strong up‐regulation of GPR84 mRNA
in such conditions, it has been suggested that GPR84 could also be a
useful marker for activation of glial cells following CNS damage. In
addition to up‐regulation of GPR84 mRNA following TLR stimulation
of microglia and astrocytes in vitro, GPR84 up‐regulation has also
been noted in vivo, for example, following La Crosse virus infection,
which results in considerable neuronal cell death and inflammation in
the CNS (Madeddu et al., 2015). Similarly, Gamo et al. (2008) also
reported up‐regulation of GPR84 mRNA in mouse brain following
hypoglossal axotomy (motor nerve injury). Higher expression of
GPR84 observed during inflammation and injury also supports the
premise that targeting GPR84 might have therapeutic value in
neuroinflammatory CNS disorders.
7 | MODULATING GPR84 ACTIVITY:
FURTHER THERAPEUTIC OPPORTUNITIES?
As highlighted above, improved availability of various GPR84 ligands
as well as GPR84 knockout mice has enhanced understanding of
receptor function and is now allowing assessment of whether
blockade of GPR84 might have therapeutic utility in various inflamma-
tory and fibrotic conditions. However, a series of studies have also
made potential links with other conditions including pain, atheroscle-
rosis, and even metabolic disorders. A key study directly exploring the
role of GPR84 in nociceptive transmission reported lack of pain
hypersensitivity in GPR84 knockout mice following peripheral nerve
injury. Consistent with this observation, up‐regulation of GPR84
mRNA and anti‐inflammatory macrophage markers (Arg‐1 and cyto-
kine Il‐10) were also reported in spinal cord and sciatic nerve after
partial sciatic nerve ligation (PNL) (Nicol et al., 2015). This study
provides a rationale for further investigating the potential role of
GPR84 in chronic pain states using low MW antagonists in mouse
models to relieve inflammatory pain. Despite this, in vivo studies have
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demonstrated that antagonism of GPR84 might be harmful in aspects
of neurodegeneration. In APP‐PS1, lack of GPR84 expression had sig-
nificant effect on disease progression, as APP‐PS1 GPR84‐deficient
mice were shown to have reduced β‐amyloid‐induced microgliosis.
These mice also demonstrated higher impairment of dendritic integrity
and cognitive function (Audoy‐Remus et al., 2015). Although these
data highlight the potentially deleterious effects of GPR84 antago-
nism, it is not clear whether activating GPR84 may be beneficial in
slowing disease progression and therefore further study is needed to
clarify the role(s) of this GPCR.
A limited number of studies have also shown how activation of
GPR84 may be beneficial in metabolic diseases. Such studies have
highlighted a possible role of GPR84 in lipid metabolism. Higher levels
of hepatic triglyceride were reported in GPR84 knockout mice
maintained on a MCFA‐enriched diet. This study, however, did not
find any influence of GPR84 activity on body weight or glucose
tolerance (Du Toit et al., 2018). Conversely, another group reported a
role of GPR84, in both glucose tolerance and reduced insulin plasma
levels in mice and pancreatic islets (Montgomery et al., 2019).
Interestingly, this study also emphasised how GPR84 might be
involved in mitochondrial metabolism. Loss of GPR84 led to impaired
mitochondria and increased oxidative stress. Despite the observed
differences in measures of glucose tolerance, these findings support
the notion that activation of GPR84 may be beneficial as a therapeutic
strategy for metabolic dysfunction associated with obesity. This is
consistent with another study reporting anti‐atherosclerotic effects of
GPR84 agonism. Activation of GPR84 by embelin leads to release of
PGE2 from human macrophages. GPR84 agonism also up‐regulates
expression of the cholesterol transporters ABCA1 and ABCG1 and
induces a significant increase in apolipoprotein A‐I‐mediated efflux of
cholesterol (Gaidarov et al., 2018). As opposed to inflammatory
conditions, where inhibiting GPR84 function may serve a potential
therapeutic benefit, agonism of GPR84 may be beneficial for its
anti‐atherosclerotic properties.
8 | CONCLUSIONS AND FUTURE
PERSPECTIVES
Although identified and subsequently shown to respond to MCFAs
more than 15 years ago, recent years have provided substantial
advances in understanding of the basic biology and regulation of
GPR84, and these have resulted in ongoing clinical trials targeting this
receptor in fibrotic conditions. However, there are many areas where
additional information would greatly facilitate the drive towards
clinical validation. These include direct structural information of the
mode(s) of binding of various classes of ligands to the receptor and
indeed the availability of a broader range of, particularly antagonist,
ligands. Although clear definition of the true endogenous regulator(s)
of this receptor would be welcome, this is unlikely to restrict efforts
to target this receptor, but recent indications of distinct functional
outcomes of agonist ligands with substantial signalling “bias” are likely
to promote efforts to understand, in greater detail, ways to harness
the differences between actions of distinct agonists also in a
therapeutic context. Equally, although measures of regulated mRNA
levels have been insightful, the ability to quantify such effects more
directly at the protein level, whether by the development of improved
radiopharmaceuticals, including potential PET ligands, or indeed via
the availability of suitable antibody tools, would offer many novel
opportunities. There is certainly potential for inflammation‐induced
up‐regulation of GPR84 mRNA to provide a sensitive and valuable
preclinical biomarker, and as well as peripheral disorders, blockade of
GPR84 may be of value in the treatment of neuroinflammatory
conditions in the CNS. Further insights into this receptor are now
likely to emerge rapidly.
8.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked
to corresponding entries in the IUPHAR/BPS Guide to
PHARMACOLOGY (http://www.guidetopharmacology.org) and are
permanently archived in the Concise Guide to PHARMACOLOGY
2019/20 (Alexander, Christopoulos et al., 2019; Alexander, Cidlowski
et al., 2019; Alexander, Fabbro et al., 2019a, 2019b; Alexander, Kelly
et al., 2019a, 2019b).
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